Media Release: Allianz extends Worldwide Olympic & Paralympic Partnership through 2032
Faster, Higher, Stronger – Together: Following the unique Olympic and Paralympic Games Paris 2024, Allianz and the International Olympic Committee (IOC) announced today that they will extending their Worldwide Olympic & Paralympic Partnership (TOP Partnership) for four more years until 2032.
As the Official Worldwide Insurance Partner, Allianz will support the Olympic and Paralympic Movements for an additional Games cycle, which includes the Olympic and Paralympic Winter Games French Alps 2030 and the Olympic and Paralympic Games Brisbane 2032 (Australia), uniting athletes and billions of fans in peaceful competition in the company's 70 markets around the world. Allianz manages risks, provides protection for organizers, participants and spectators, and supports athletes through mentoring and career opportunities. The 2030 and 2032 Games will take place in two of Allianz’s core markets, France and Australia, which contributed more than 10% of the operating profit of Allianz in 2024.
Allianz, one of the world's leading insurers and the strongest insurance brand, has been the Official Worldwide Insurance Partner to the Olympic Movement since 2021 supporting the preparation and delivery of Paris 2024, Milano Cortina 2026 and LA 2028. Allianz has also supported the International Paralympic Committee since 2006, becoming a “Worldwide Paralympic Partner” in 2021. The partnership with the Olympic and Paralympic Movements complements Allianz’s "Power of Unity" program which helps bring individuals and organizations together to foster inclusive prosperity through togetherness, connection and common understanding.
Paris 2024: Record viewership
A record 84% of the potential global audience followed the Olympic Games Paris 2024 according to independent research conducted on the IOC’s behalf. This equates to around five billion people and means that more than half of the world’s population followed the inspirational achievements of the Olympic athletes and the cohesive magic of the Olympic Games in Paris.
The Paris 2024 Paralympic Games were the biggest and best yet, setting a new benchmark for all future Games editions. They brought together a record 169 competing delegations and 4,400 athletes and were broadcast by 225 Media Rights Holders, more than ever before. Highlighting the growing global appeal of the Paralympic Games, the number of live TV hours viewed, excluding the host market, increased by 83% compared to Tokyo 2020.
Allianz CEO Oliver Bäte said: “The Olympic and Paralympic Games Paris 2024 inspired the world as well as our employees, customers and business partners, elevating and uniting people through sport. We also saw very positive benefits for our business and the Allianz brand. We are therefore delighted – particularly against the backdrop of an increasingly divided world – to extend this successful partnership through 2032 and continue our support for the unifying spirit of the Olympic and Paralympic Movements.”
IOC President Thomas Bach said: “We are delighted that following the success of the Olympic Games Paris 2024, we will extend our partnership with Allianz for another four years. Allianz is a world leader in its industry and believes in the Olympic vision of building a better world through sport, and supports our commitment to athletes around the world. Now more than ever the world needs the power of sports to unite people. The IOC and Allianz share this vision and this is why we consider our partnership more important than ever.”
Andrew Parsons, President of the International Paralympic Committee (IPC), said: “Allianz’s journey with the IPC began in 2006 and our partnership and joint passion for making the world a better place has grown stronger each and every day, having a tremendous impact across the Paralympic Movement. We are greatly looking forward to our partnership with Allianz surpassing a quarter of a century with the extension of this agreement through to 2032. It gives us even more confidence in what we can achieve together in the future to make for a more inclusive world through Para sport.”
Jiří Kejval, Chair of the IOC’s Revenues and Commercial Partnerships Commission, said: “Allianz is a great supporter of the Olympic and Paralympic Movements. The company has built a world leading business founded on trust, which underlines the importance of the trust and commitment Allianz has placed in our partnership. We are very proud to be working together with Allianz until 2032.”
People, business, brand
At the recent Olympic and Paralympic Games Paris 2024, Allianz played a multi-faceted role, providing comprehensive insurance coverage, strong support for athletes, and campaigns in more than 60 markets around the world that connected employees, customers, business partners and fans to the shared vision of building a better world through sport.
As the global insurance partner, Allianz helped ensuring the smooth and secure delivery of the Games, protecting athletes, fans and the many actors of the sports ecosystem from start to finish often through ‘intangible’ solutions and services across 15 lines of business. Allianz rolled out a comprehensive medical assistance program for 155,000 athletes, staff, volunteers and members of the Olympic and Paralympic family, provided ticket cancellation insurance for fans and delivered property and liability coverage for many sports venues.
Through its global “Get Ready for the Best” campaign focused on the importance of preparation through various market activities and digital campaigns across more than 60 countries, Allianz fostered a deep connection with the Olympic spirit and engaged new target groups. Since the partnership began in 2021, awareness of the partnership among consumers has increased by double-digit percentage points. This has supported performance on key brand-related metrics such as brand likeability and purchase consideration. Allianz’s brand value has been estimated at 23.8 billion USD according to Interbrand.
Allianz runs a dedicated athlete support program, Team Allianz, comprising over 100 athletes across the globe. This includes a year-round mentoring Buddy Program and financial literacy initiatives that help athletes manage sports, personal finance and their professional careers. Allianz also leads the MoveNow Program, encouraging young people globally to stay active by providing access and opportunities.
Downloads | Further links | |
About Allianz
The Allianz Group is one of the world's leading insurers and asset managers with around 128 million* private and corporate customers in nearly 70 countries. Allianz customers benefit from a broad range of personal and corporate insurance services, ranging from property, life and health insurance to assistance services to credit insurance and global business insurance. Allianz is one of the world’s largest investors, managing around 776 billion euros** on behalf of its insurance customers. Furthermore, our asset managers PIMCO and Allianz Global Investors manage about 1.9 trillion euros** of third-party assets. Thanks to our systematic integration of ecological and social criteria in our business processes and investment decisions, we are among the leaders in the insurance industry in the Dow Jones Sustainability Index. In 2024, over 156,000 employees achieved a total business volume of 179.8 billion euros and an operating profit of 16.0 billion euros for the group.
* Including non-consolidated entities with Allianz customers.
**As of December 31, 2024.
About the International Olympic Committee (IOC)
The International Olympic Committee is a not-for-profit, civil, non-governmental, international organization made up of volunteers which is committed to building a better world through sport. It redistributes more than 90 per cent of its income to the wider sporting movement, which means that every day the equivalent of USD 4.2 million goes to help athletes and sports organizations at all levels around the world.
About the International Paralympic Committee (IPC)
The International Paralympic Committee (IPC) is the global governing body of the Paralympic Movement and is based in Bonn, Germany.Founded in 1989 as an international non-profit organisation, we aim to be athlete-centered and membership-focused in all our endeavors. The IPC’s vision is to make for an inclusive world through Para sport, while our mission is to lead the Paralympic Movement, oversee the delivery of the Paralympic Games and support members to enable Para athletes to achieve sporting excellence.
Mandatory corporate information:Corporate disclosures
These assessments are, as always, subject to the disclaimer provided below.
Cautionary note regarding forward-looking statements
This document includes forward-looking statements, such as prospects or expectations, that are based on management's current views and assumptions and subject to known and unknown risks and uncertainties. Actual results, performance figures, or events may differ significantly from those expressed or implied in such forward-looking statements.
Deviations may arise due to changes in factors including, but not limited to, the following: (i) the general economic and competitive situation in the Allianz’s core business and core markets, (ii) the performance of financial markets (in particular market volatility, liquidity, and credit events), (iii) adverse publicity, regulatory actions or litigation with respect to the Allianz Group, other well-known companies and the financial services industry generally, (iv) the frequency and severity of insured loss events, including those resulting from natural catastrophes, and the development of loss expenses, (v) mortality and morbidity levels and trends, (vi) persistency levels, (vii) the extent of credit defaults, (viii) interest rate levels, (ix) currency exchange rates, most notably the EUR/USD exchange rate, (x) changes in laws and regulations, including tax regulations, (xi) the impact of acquisitions including related integration issues and reorganization measures, and (xii) the general competitive conditions that, in each individual case, apply at a local, regional, national, and/or global level. Many of these changes can be exacerbated by terrorist activities.
No duty to update
Allianz assumes no obligation to update any information or forward-looking statement contained herein, save for any information we are required to disclose by law.
Privacy Note
Allianz SE is committed to protecting your personal data. Find out more in our privacy statement.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250312366232/en/
Contacts
For further information please contact:
Lauren Day Tel. +49 89 3800 3345 E-Mail: lauren.day@allianz.com
Florian Amberg Tel. +49 89 3800 15924 E-Mail: florian.amberg@allianz.com
Heidi Polke Tel. +49 89 3800 90777 E-Mail: heidi.polke@allianz.com
IOC Media Team Tel. +41 21 621 60 00 E-Mail: pressoffice@olympic.org
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press Release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom